Pharmaniaga Berhad, an investment holding company, operates as an integrated pharmaceutical company in Malaysia, Indonesia, and internationally. More Details
Fair value with limited growth.
Share Price & News
How has Pharmaniaga Berhad's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PHARMA is more volatile than 75% of MY stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: PHARMA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of MY stocks.
7 Day Return
1 Year Return
Return vs Industry: PHARMA underperformed the MY Healthcare industry which returned 9.4% over the past year.
Return vs Market: PHARMA exceeded the MY Market which returned -0.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Pharmaniaga Berhad's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StTaking A Look At Pharmaniaga Berhad's (KLSE:PHARMA) ROE
2 months ago | Simply Wall StPharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet
2 months ago | Simply Wall StIf You Had Bought Pharmaniaga Berhad (KLSE:PHARMA) Stock A Year Ago, You Could Pocket A 99% Gain Today
Is Pharmaniaga Berhad undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PHARMA (MYR0.82) is trading below our estimate of fair value (MYR3.7)
Significantly Below Fair Value: PHARMA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PHARMA is good value based on its PE Ratio (38x) compared to the MY Healthcare industry average (56.8x).
PE vs Market: PHARMA is poor value based on its PE Ratio (38x) compared to the MY market (17.1x).
Price to Earnings Growth Ratio
PEG Ratio: PHARMA is poor value based on its PEG Ratio (2.4x)
Price to Book Ratio
PB vs Industry: PHARMA's PB Ratio (3x) is in line with the MY Healthcare industry average.
How is Pharmaniaga Berhad forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHARMA's forecast earnings growth (15.7% per year) is above the savings rate (3.6%).
Earnings vs Market: PHARMA's earnings (15.7% per year) are forecast to grow faster than the MY market (10.9% per year).
High Growth Earnings: PHARMA's earnings are forecast to grow, but not significantly.
Revenue vs Market: PHARMA's revenue (1.7% per year) is forecast to grow slower than the MY market (6.1% per year).
High Growth Revenue: PHARMA's revenue (1.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PHARMA's Return on Equity is forecast to be low in 3 years time (15.5%).
How has Pharmaniaga Berhad performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PHARMA has high quality earnings.
Growing Profit Margin: PHARMA became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: PHARMA's earnings have declined by 46.5% per year over the past 5 years.
Accelerating Growth: PHARMA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PHARMA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (-7.8%).
Return on Equity
High ROE: PHARMA's Return on Equity (7.1%) is considered low.
How is Pharmaniaga Berhad's financial position?
Financial Position Analysis
Short Term Liabilities: PHARMA's short term assets (MYR1.2B) do not cover its short term liabilities (MYR1.5B).
Long Term Liabilities: PHARMA's short term assets (MYR1.2B) exceed its long term liabilities (MYR32.3M).
Debt to Equity History and Analysis
Debt Level: PHARMA's debt to equity ratio (209.9%) is considered high.
Reducing Debt: PHARMA's debt to equity ratio has increased from 110.4% to 209.9% over the past 5 years.
Debt Coverage: PHARMA's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: PHARMA's interest payments on its debt are not well covered by EBIT (2.2x coverage).
What is Pharmaniaga Berhad current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PHARMA's dividend (0.98%) isn’t notable compared to the bottom 25% of dividend payers in the MY market (1.49%).
High Dividend: PHARMA's dividend (0.98%) is low compared to the top 25% of dividend payers in the MY market (4.17%).
Stability and Growth of Payments
Stable Dividend: PHARMA's dividend payments have been volatile in the past 10 years.
Growing Dividend: PHARMA's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (83.4%), PHARMA's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: PHARMA's dividends in 3 years are forecast to be covered by earnings (70.8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Zulkarnain Bin Md Eusope (53 yo)
Datuk Zulkarnain Bin Md Eusope serves as Commissioner at PT Millennium Pharmacon International Tbk since May, 2021. He has been Group Managing Director of Pharmaniaga Berhad since September 1, 2020 and has...
CEO Compensation Analysis
Compensation vs Market: Zulkarnain's total compensation ($USD200.09K) is about average for companies of similar size in the MY market ($USD192.52K).
Compensation vs Earnings: Insufficient data to compare Zulkarnain's compensation with company performance.
Experienced Management: PHARMA's management team is seasoned and experienced (7.1 years average tenure).
Experienced Board: PHARMA's board of directors are not considered experienced ( 0.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pharmaniaga Berhad's company bio, employee growth, exchange listings and data sources
- Name: Pharmaniaga Berhad
- Ticker: PHARMA
- Exchange: KLSE
- Founded: 1994
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: RM1.074b
- Shares outstanding: 1.31b
- Website: https://www.pharmaniaga.com
Number of Employees
- Pharmaniaga Berhad
- No. 7, Lorong Keluli 1B
- Kawasan Perindustrian Bukit Raja Selatan
- Shah Alam
Pharmaniaga Berhad, an investment holding company, operates as an integrated pharmaceutical company in Malaysia, Indonesia, and internationally. The company operates through three segments: Logistics and D...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/30 16:48|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.